"Given these data suggest a potentially important clinical benefit in a pre-defined sub-group of high-risk patients and the public health need, GSK has decided to amend the OSCAR study to expand this cohort to confirm these potentially significant findings"
Is this not what CytoDyn has done/is doing with leronlimab?
News 
Market Data 
Discover 
AI
